Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Simultaneous motion monitoring and truth-in-delivery analysis imaging framework for MR-guided radiotherapy.

Mickevicius NJ, Chen X, Boyd Z, Lee HJ, Ibbott GS, Paulson ES.

Phys Med Biol. 2018 Nov 26;63(23):235014. doi: 10.1088/1361-6560/aaec91.

PMID:
30474614
2.

Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1).

Kowanetz M, Zou W, Gettinger SN, Koeppen H, Kockx M, Schmid P, Kadel EE 3rd, Wistuba I, Chaft J, Rizvi NA, Spigel DR, Spira A, Hirsch FR, Cohen V, Smith D, Boyd Z, Miley N, Flynn S, Leveque V, Shames DS, Ballinger M, Mocci S, Shankar G, Funke R, Hampton G, Sandler A, Amler L, Mellman I, Chen DS, Hegde PS.

Proc Natl Acad Sci U S A. 2018 Oct 23;115(43):E10119-E10126. doi: 10.1073/pnas.1802166115. Epub 2018 Oct 8.

3.

Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab.

Vennapusa B, Baker B, Kowanetz M, Boone J, Menzl I, Bruey JM, Fine G, Mariathasan S, McCaffery I, Mocci S, Rost S, Smith D, Dennis E, Tang SY, Damadzadeh B, Walker E, Hegde PS, Williams JA, Koeppen H, Boyd Z.

Appl Immunohistochem Mol Morphol. 2019 Feb;27(2):92-100. doi: 10.1097/PAI.0000000000000594.

4.

Current Status of Companion and Complementary Diagnostics: Strategic Considerations for Development and Launch.

Scheerens H, Malong A, Bassett K, Boyd Z, Gupta V, Harris J, Mesick C, Simnett S, Stevens H, Gilbert H, Risser P, Kalamegham R, Jordan J, Engel J, Chen S, Essioux L, Williams JA.

Clin Transl Sci. 2017 Mar;10(2):84-92. doi: 10.1111/cts.12455. Epub 2017 Feb 27.

5.

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.

Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A, Hoffman-Censits J, Perez-Gracia JL, Dawson NA, van der Heijden MS, Dreicer R, Srinivas S, Retz MM, Joseph RW, Drakaki A, Vaishampayan UN, Sridhar SS, Quinn DI, Durán I, Shaffer DR, Eigl BJ, Grivas PD, Yu EY, Li S, Kadel EE 3rd, Boyd Z, Bourgon R, Hegde PS, Mariathasan S, Thåström A, Abidoye OO, Fine GD, Bajorin DF; IMvigor210 Study Group.

Lancet. 2017 Jan 7;389(10064):67-76. doi: 10.1016/S0140-6736(16)32455-2. Epub 2016 Dec 8. Erratum in: Lancet. 2017 Aug 26;390(10097):848.

6.

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer.

Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, Bellmunt J, Burris HA, Petrylak DP, Teng SL, Shen X, Boyd Z, Hegde PS, Chen DS, Vogelzang NJ.

Nature. 2014 Nov 27;515(7528):558-62. doi: 10.1038/nature13904.

PMID:
25428503
7.

Developing a center for nursing research: an influence on nursing education and research through mentorship.

Krause-Parello CA, Sarcone A, Samms K, Boyd ZN.

Nurse Educ Pract. 2013 Mar;13(2):106-12. doi: 10.1016/j.nepr.2012.08.004. Epub 2012 Sep 7.

PMID:
22959470
8.

Human-canine interaction: exploring stress indicator response patterns of salivary cortisol and immunoglobulin A.

Krause-Parello CA, Tychowski J, Gonzalez A, Boyd Z.

Res Theory Nurs Pract. 2012;26(1):25-40.

PMID:
22866562
9.

miR-221/222 targeting of trichorhinophalangeal 1 (TRPS1) promotes epithelial-to-mesenchymal transition in breast cancer.

Stinson S, Lackner MR, Adai AT, Yu N, Kim HJ, O'Brien C, Spoerke J, Jhunjhunwala S, Boyd Z, Januario T, Newman RJ, Yue P, Bourgon R, Modrusan Z, Stern HM, Warming S, de Sauvage FJ, Amler L, Yeh RF, Dornan D.

Sci Signal. 2011 Aug 9;4(186):pt5. doi: 10.1126/scisignal.2002258.

PMID:
21868360
10.

TRPS1 targeting by miR-221/222 promotes the epithelial-to-mesenchymal transition in breast cancer.

Stinson S, Lackner MR, Adai AT, Yu N, Kim HJ, O'Brien C, Spoerke J, Jhunjhunwala S, Boyd Z, Januario T, Newman RJ, Yue P, Bourgon R, Modrusan Z, Stern HM, Warming S, de Sauvage FJ, Amler L, Yeh RF, Dornan D.

Sci Signal. 2011 Jun 14;4(177):ra41. doi: 10.1126/scisignal.2001538.

11.

Veterinary medicine as portrayed on postcards.

Boyd ZT.

Hist Med Vet. 2011;36(1-3):3-123. No abstract available.

PMID:
22849247
12.

Raccoon roundworm encephalitis.

Mehta P, Boyd Z, Cully B.

Pediatr Radiol. 2010 Nov;40(11):1834-6. doi: 10.1007/s00247-010-1625-7. Epub 2010 Apr 17.

PMID:
20411256
13.

In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models.

Hoeflich KP, O'Brien C, Boyd Z, Cavet G, Guerrero S, Jung K, Januario T, Savage H, Punnoose E, Truong T, Zhou W, Berry L, Murray L, Amler L, Belvin M, Friedman LS, Lackner MR.

Clin Cancer Res. 2009 Jul 15;15(14):4649-64. doi: 10.1158/1078-0432.CCR-09-0317. Epub 2009 Jun 30.

14.

A tumor sorting protocol that enables enrichment of pancreatic adenocarcinoma cells and facilitation of genetic analyses.

Boyd ZS, Raja R, Johnson S, Eberhard DA, Lackner MR.

J Mol Diagn. 2009 Jul;11(4):290-7. doi: 10.2353/jmoldx.2009.080124. Epub 2009 May 21.

15.

Pediatric salivary gland imaging.

Boyd ZT, Goud AR, Lowe LH, Shao L.

Pediatr Radiol. 2009 Jul;39(7):710-22. doi: 10.1007/s00247-009-1232-7. Epub 2009 Mar 27. Review.

PMID:
19326110
16.

Proteomic analysis of breast cancer molecular subtypes and biomarkers of response to targeted kinase inhibitors using reverse-phase protein microarrays.

Boyd ZS, Wu QJ, O'Brien C, Spoerke J, Savage H, Fielder PJ, Amler L, Yan Y, Lackner MR.

Mol Cancer Ther. 2008 Dec;7(12):3695-706. doi: 10.1158/1535-7163.MCT-08-0810. Epub 2008 Dec 3.

17.

Transcriptional control of human T-BET expression: the role of Sp1.

Yu J, Wei M, Boyd Z, Lehmann EB, Trotta R, Mao H, Liu S, Becknell B, Jaung MS, Jarjoura D, Marcucci G, Wu LC, Caligiuri MA.

Eur J Immunol. 2007 Sep;37(9):2549-61.

18.

MRI tumor characterization using Gd-GlyMe-DOTA-perfluorooctyl-mannose-conjugate (Gadofluorine M), a protein-avid contrast agent.

Raatschen HJ, Swain R, Shames DM, Fu Y, Boyd Z, Zierhut ML, Wendland MF, Misselwitz B, Weinmann HJ, Wolf KJ, Brasch RC.

Contrast Media Mol Imaging. 2006 May-Jun;1(3):113-20.

PMID:
17193687
19.

Pro- and antiinflammatory cytokine signaling: reciprocal antagonism regulates interferon-gamma production by human natural killer cells.

Yu J, Wei M, Becknell B, Trotta R, Liu S, Boyd Z, Jaung MS, Blaser BW, Sun J, Benson DM Jr, Mao H, Yokohama A, Bhatt D, Shen L, Davuluri R, Weinstein M, Marcucci G, Caligiuri MA.

Immunity. 2006 May;24(5):575-90.

20.

Interleukin-10 receptor signaling through STAT-3 regulates the apoptosis of retinal ganglion cells in response to stress.

Boyd ZS, Kriatchko A, Yang J, Agarwal N, Wax MB, Patil RV.

Invest Ophthalmol Vis Sci. 2003 Dec;44(12):5206-11.

PMID:
14638718

Supplemental Content

Support Center